Summit’s biomarker data has the potential to monitor utrophin modulation activity and distinguish between repairing and mature muscle fibres in DMD muscle biopsies at the single fibre level. This promising biomarker programme will support and help inform the development of SMT C1100, Summit’s lead utrophin modulator, and its second and future utrophin modulators. SMT C1100 met its primary objective in its Phase Ib modified diet clinical trial in August and received approval to initiate a Phase II proof of concept clinical trial, PhaseOut DMD, in January. There is currently no cure for DMD, a fatal muscle wasting Orphan disease in the US and Europe, which affects 1 in 3,500 male births, and unlike other approaches in development Summit’s utrophin modulation programme is a potential disease modifying approach that could potentially be used by 100% of boys with DMD and in combination with other agents. We look forward to data from the first group of patients in the PhaseOut trial from H2 2016 onwards.
